Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790248 | 0.83 | MAPT (0.42) | MAPTRAB9ANPC1AKR1C3AKR1C2 | |
| SCHEMBL50489 | 0.78 | AKR1C3 (0.49) | MAPTRAB9ANPC1AKR1C3AKR1C2 | |
| SCHEMBL29361599 | 0.78 | AKR1C3 (0.49) | MAPTRAB9ANPC1AKR1C3AKR1C2 | |
| SCHEMBL3502920 | 0.78 | ALDH1A1 (0.42) | MAPTRAB9ANPC1CYP2A6PKM | |
| SCHEMBL13128973 | 0.75 | CYP2A6 (0.46) | MAPTRAB9ANPC1S100A4CYP2A6 | |
| SCHEMBL31050823 | 0.75 | PKM (0.53) | MAPTRAB9ANPC1S100A4CYP2A6 | |
| SCHEMBL12620176 | 0.75 | ALDH1A1 (0.58) | MAPTRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL1669169 | 0.74 | CYP2A6 (0.48) | MAPTRAB9ANPC1AKR1C3AKR1C2 | |
| SCHEMBL7295677 | 0.74 | PKM (0.57) | MAPTRAB9ANPC1AKR1C3AKR1C2 | |
| SCHEMBL7295671 | 0.74 | AKR1C3 (0.46) | MAPTRAB9ANPC1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885RAB9A 1357/4885NPC1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.